Reported about 15 hours ago
Vertex Pharmaceuticals has reported a stronger-than-expected fourth-quarter revenue of $2.91 billion and provided an optimistic revenue forecast for 2025, estimated between $11.75 billion and $12 billion, marking nearly 20% growth. Despite a slight decrease in adjusted earnings due to rising expenses and lower income, the approval of their new non-opioid painkiller, Journavx, bolstered confidence in their future performance.
Source: YAHOO